By Josh Beckerman

Switzerland-based biotechnology company ADC Therapeutics SA has filed for an initial public offering.

ADC focuses on hematological malignancies and solid tumors.

The company plans to trade on the New York Stock Exchange under symbol ADCT. The filing lists an amount of $150 million.

Auven Therapeutics owns 42.7% stake of ADC. AstraZeneca PLC (AZN) owns 7.1%.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 06, 2019 20:11 ET (00:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Astrazeneca
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Astrazeneca